Capital Senior Living Corporation CSU
33.54 +33.54
Day range unavailable
52-week range unavailable
News
defenseworld.net Constellation Software (TSE:CSU) Shares Pass Above 200 Day Moving Average – What’s Next? Constellation Software Inc. (TSE: CSU - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of C$2,766.05 and traded…
marketbeat.com Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses Celldex Therapeutics NASDAQ: CLDX reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained…
globenewswire.com Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSU EMBARQ-CSU1 and -CSU2 met primary and all key…
marketbeat.com Constellation Software Q2 Earnings Call Highlights Constellation Software TSE: CSU used its second-quarter conference call to outline its approach to artificial intelligence, vertical-market organization and acquisitions, while executives addressed…
businesswire.com CSU Digital Launches U.S. Market Expansion at New York Executive Summit MIAMI--(BUSINESS WIRE)--CSU Digital is Latin America's largest independent card processor, managing more than 50 million cards and processing nearly $100 billion in annual transactions. This week,…
zacks.com 4 P&C Insurers Stocks Poised to Weather 2026 Hurricane Season HCI, PGR, ALL and PLMR are positioned to stay resilient as CSU sees a milder 2026 hurricane season, prudent pricing, increased exposure and increased digitalization.
globenewswire.com Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the…
marketbeat.com This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason When thinking about America's neighbors in the Great White North, maple syrup, hockey, and poutine routinely come to mind. However, Canada's robust and highly sophisticated tech sector may deserve…
globenewswire.com Vertus Group Expands Operations into Mexico with Latest Acquisition MEXICO CITY, June 04, 2026 (GLOBE NEWSWIRE) -- Vertus Group, a division of Jonas Software and Constellation Software, today announced the acquisition of an undisclosed software company based in…
globenewswire.com CORA Group Acquires Finastra's Phoenix Core System, Malauzai Digital Banking and Fusion Analytics Businesses TORONTO, June 03, 2026 (GLOBE NEWSWIRE) -- CORA Group, a portfolio of Jonas Software, an operating group of Constellation Software (TSX: CSU), today announced that it has acquired Finastra's U.S.…
globenewswire.com Constellation Software Inc. Confirms Closing of DerbySoft Acquisition Through Juniper Group TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU) today announced that, through Juniper Group, an operating group of Vela Software, it has completed its previously…
seekingalpha.com Constellation Software Inc. (CSU:CA) Shareholder/Analyst Call Transcript Constellation Software Inc. (CSU:CA) Shareholder/Analyst Call Transcript
globenewswire.com Constellation Software Inc. Announces Results of Voting for Directors at Annual General Shareholders' Meeting TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc. (the “Corporation”) (TSX:CSU) is pleased to announce the results of the vote on directors at its May 15, 2026 annual general…
globenewswire.com Constellation Software Inc. Announces Results for the First Quarter Ended March 31, 2026 and Declares Quarterly Dividend TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the first quarter ended March 31, 2026 and…
seekingalpha.com Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial Celldex is positioned as a platform immunology company, leveraging barzolvolimab's mast-cell depletion mechanism beyond chronic urticaria. CLDX's robust cash position ($518.6M at 2025 year-end, $345M…
globenewswire.com Constellation Software Inc. and Topicus.Com Inc. Announce Results for Topicus.com Inc. for the First Quarter Ended March 31, 2026 TORONTO, May 05, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) in a joint release with Constellation Software Inc. (TSX:CSU) today announced financial results for Topicus.com Inc. (“Topicus”…
globenewswire.com Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU) Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program
globenewswire.com Constellation Software Inc. Announces Conference Call to Discuss First Quarter Results TORONTO, April 15, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it will host a first quarter conference call and live audio webcast on May 13, 2026 at 8:00 a.m. ET.
globenewswire.com Constellation Software's Vela Operating Group Enters into Agreement to acquire a majority interest in Derbysoft Holdings Limited TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc. (“Constellation”) (TSX:CSU) today announced that Juniper Group, an operating group of Vela Software, has entered into a…
globenewswire.com Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly…
benzinga.com Earnings Scheduled For November 11, 2021 Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million.
benzinga.com Earnings Scheduled For November 4, 2021 Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
benzinga.com 78 Biggest Movers From Friday Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering.
benzinga.com Earnings Scheduled For August 12, 2021 Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
benzinga.com Earnings Scheduled For August 4, 2021 Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.- benzinga.com Stocks That Hit 52-Week Highs On Wednesday Wednesday's morning session saw 12 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday Tuesday's morning session saw 241 companies set new 52-week highs.
- benzinga.com Earnings Scheduled For May 13, 2021 Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
benzinga.com Stocks That Hit 52-Week Highs On Wednesday During Wednesday's morning trading, 57 companies set new 52-week highs.
benzinga.com Earnings Scheduled For May 5, 2021 Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.- benzinga.com Stocks That Hit 52-Week Highs On Monday Monday's morning session saw 240 companies set new 52-week highs.
- benzinga.com Earnings Scheduled For November 5, 2020 Companies Reporting Before The Bell • Bluerock Residential Growth REIT, Inc. Class A Common Stock (AMEX:BRG) is expected to report quarterly loss at $0.64 per share on revenue of $52.59 million.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday
- benzinga.com Stocks That Hit 52-Week Lows On Friday
benzinga.com 50 Biggest Movers From Yesterday 
benzinga.com 75 Biggest Movers From Yesterday - benzinga.com Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018
- benzinga.com Stocks Which Set New 52-Week Low Yesterday, August 6th
- benzinga.com Stocks Which Set New 52-Week Lows Friday, August 3rd
benzinga.com Stocks Which Set New 52-Week Low Yesterday, August 2nd - benzinga.com Stocks Which Set New 52-Week Low Yesterday, August 1st
- benzinga.com 66 Biggest Movers From Yesterday